TIM
TPST icon

Tortoise Investment Management’s Tempest Therapeutics TPST Stock Holding History

Tortoise Investment Management’s Portfolio TPST Stock Details TPST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-1
Closed -$3K – 569
2018
Q2 		$3K Hold
1
– – ﹤0.01% 507
2018
Q1 		$3K Hold
1
– – ﹤0.01% 488
2017
Q4 		$5K Hold
1
– – ﹤0.01% 458
2017
Q3 		$5K Hold
1
– – ﹤0.01% 414
2017
Q2 		$5K Buy
+1
New +$4.23K ﹤0.01% 411

Other funds holding TPST

PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
GC
GMT Capital Atlanta, Georgia $2.19B AUM 72.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Tortoise Investment Management's TPST Position: Q3 2018 in Review

Tortoise Investment Management sold out of Tempest Therapeutics (TPST) in Q3 2018, closing a stake of 1 share — an estimated $3K sold.

Tortoise Investment Management first reported a position in TPST in Q2 2017 and held it in 5 quarters. The position peaked at $5K in Q4 2017. 35 funds tracked by Wall St. Rank hold TPST as of Q3 2018.

  • Tortoise Investment Management reported no remaining Tempest Therapeutics position as of Q3 2018 after selling out during the quarter.
  • Tortoise Investment Management sold 1 Tempest Therapeutics share in Q3 2018, an estimated $3K.
  • Tortoise Investment Management first reported a position in Tempest Therapeutics in Q2 2017 and held it in 5 quarters.
  • Tortoise Investment Management's Tempest Therapeutics position peaked at $5K in Q4 2017.
  • 35 funds tracked by Wall St. Rank held Tempest Therapeutics as of Q3 2018.

Based on Tortoise Investment Management's 13F filing for Q3 2018, filed 20 Nov 2018.